Literature DB >> 9467684

NSAIDs and blood pressure. Clinical importance for older patients.

A G Johnson1.   

Abstract

The use of nonsteroidal anti-inflammatory drugs (NSAIDs) and antihypertensive medication increases with age to 26% and > 50%, respectively, among the elderly. Overall, 12 to 15% of elderly individuals take at least 1 NSAID and an antihypertensive medication concurrently. A large case-control study of older individuals demonstrated that recent users of NSAIDs had a 1.7-fold increase in risk of initiating antihypertensive therapy compared with non-users. A community-based epidemiological study revealed that NSAID use significantly predicted the presence of hypertension (odds ratio 1.4, 95% confidence interval 1.1 to 1.7) in the elderly. Furthermore, among those taking antihypertensive agents in the 65+ Rural Health Study, in Iowa, US, individuals also taking NSAIDs had a mean systolic blood pressure (BP) 4.9 mm Hg higher than non-users of NSAIDs. The hypertensive effect of NSAIDs varies depending on the specific NSAID used and the type of antihypertensive agent, if they are taken concurrently. While the results of randomised, controlled trials in the elderly have been conflicting, 2 meta-analyses involving younger adults have revealed that NSAID use produces a clinically significant increment in mean BP of 5.0 mm Hg, which is most marked in patients with controlled hypertension. Stratification by NSAID type has revealed that piroxicam and indomethacin had the greatest, and sulindac the least, pressor effect. While the mechanisms) of the pressor effect remain speculative, salt and water retention, caused by several factors operating in parallel, coupled with an increased total peripheral vascular resistance via increased renal endothelin-1 synthesis, are potentially important. A 5 to 6 mm Hg increase in diastolic BP maintained over a few years may be associated with a 67% increase in total stroke occurrence and a 15% increase in events associated with coronary heart disease. Clinicians should strive to avoid excessive use of NSAID treatment and consider alternative, well-tolerated therapeutic options, including simple analgesics and physical therapy. For patients who require concomitant NSAID and antihypertensive treatment, clinicians should be aware of the greater hypertensive effect of indomethacin and piroxicam compared with alternative NSAIDs, and the potential for relatively greater antagonism by NSAIDs of the BP-lowering effect of beta-blockers compared with other antihypertensives. Finally, the progress of each patient should be monitored by careful BP measurement particularly during the initiation of NSAID therapy.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9467684     DOI: 10.2165/00002512-199812010-00003

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   3.923


  84 in total

Review 1.  Rheumatoid arthritis and osteoarthritis: current and future therapies.

Authors:  B L Flynn
Journal:  Am Pharm       Date:  1994-11

2.  Effects of indomethacin, sulindac, naproxen, aspirin, and paracetamol in treated hypertensive patients.

Authors:  J P Chalmers; M J West; L M Wing; A J Bune; J R Graham
Journal:  Clin Exp Hypertens A       Date:  1984

3.  Attenuation of hypotensive effect of propranolol and thiazide diuretics by indomethacin.

Authors:  J Watkins; E C Abbott; C N Hensby; J Webster; C T Dollery
Journal:  Br Med J       Date:  1980-09-13

4.  Rising frequency of ulcer perforation in elderly people in the United Kingdom.

Authors:  R Walt; B Katschinski; R Logan; J Ashley; M Langman
Journal:  Lancet       Date:  1986-03-01       Impact factor: 79.321

5.  The countering of diazoxide-induced vasodilatation by tenoxicam in normal volunteers.

Authors:  D K Sommers; M van Wyk; J R Snyman
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

Review 6.  Adverse drug interactions with nonsteroidal anti-inflammatory drugs (NSAIDs). Recognition, management and avoidance.

Authors:  A G Johnson; P Seideman; R O Day
Journal:  Drug Saf       Date:  1993-02       Impact factor: 5.606

7.  The antihypertensive effect of captopril in essential hypertension: relationship to prostaglandins and the kallikrein-kinin system.

Authors:  J Quilley; K L Duchin; E M Hudes; J C McGiff
Journal:  J Hypertens       Date:  1987-02       Impact factor: 4.844

8.  Flurbiprofen interaction with single doses of atenolol and propranolol.

Authors:  J Webster; J C Petrie; I McLean; G M Hawksworth
Journal:  Br J Clin Pharmacol       Date:  1984-12       Impact factor: 4.335

9.  Contribution of endogenous generation of endothelin-1 to basal vascular tone.

Authors:  W G Haynes; D J Webb
Journal:  Lancet       Date:  1994-09-24       Impact factor: 79.321

10.  The influence of prostaglandin inhibition by indomethacin on blood pressure and renal function in hypertensive patients treated with cilazapril.

Authors:  W Kirch; K Stroemer; J F Hoogkamer; C H Kleinbloesem
Journal:  Br J Clin Pharmacol       Date:  1989       Impact factor: 4.335

View more
  12 in total

Review 1.  Cardiovascular risk with cyclooxygenase inhibitors: general problem with substance specific differences?

Authors:  Irmgard Tegeder; Gerd Geisslinger
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-04-04       Impact factor: 3.000

Review 2.  Heart failure induced by non-cardiac drugs.

Authors:  Lars Slørdal; Olav Spigset
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

Review 3.  Safe pharmacologic treatment strategies for osteoarthritis pain in African Americans with hypertension, and renal and cardiac disease.

Authors:  Jerry Johnson; Joan Weinryb
Journal:  J Natl Med Assoc       Date:  2006-07       Impact factor: 1.798

4.  Decreased dromotropic response to verapamil despite pronounced increased drug concentration in rheumatoid arthritis.

Authors:  P R Mayo; K Skeith; A S Russell; F Jamali
Journal:  Br J Clin Pharmacol       Date:  2000-12       Impact factor: 4.335

5.  Nonsteroidal anti-inflammatory drug, indomethacin improves spatial memory and NMDA receptor function in aged animals.

Authors:  Ashok Kumar; Asha Rani; Rachel B Scheinert; Brandi K Ormerod; Thomas C Foster
Journal:  Neurobiol Aging       Date:  2018-06-28       Impact factor: 4.673

Review 6.  New dosage formulations for targeted delivery of cyclo-oxygenase-2 inhibitors: focus on use in the elderly.

Authors:  Shyam S Bansal; Abhijeet Joshi; Arvind K Bansal
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

Review 7.  Over-the-counter analgesics in older adults: a call for improved labelling and consumer education.

Authors:  Christianne L Roumie; Marie R Griffin
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

Review 8.  Pain treatment in multimorbid patients, the older population and other high-risk groups. The clinical challenge of reducing toxicity.

Authors:  C H Wilder-Smith
Journal:  Drug Saf       Date:  1998-06       Impact factor: 5.606

9.  Blood pressure effects of naproxcinod in hypertensive patients.

Authors:  Raymond Townsend; Neville Bittar; Jeffrey Rosen; William Smith; Andrea Ramsay; Steven G Chrysant; Robert Weiss; Aldina Pivodic; Brigitte Duquesroix; Jacques Djian
Journal:  J Clin Hypertens (Greenwich)       Date:  2011-01-25       Impact factor: 3.738

Review 10.  Non-steroidal anti-inflammatory drugs in the pharmacological management of osteoarthritis in the very old: prescribe or proscribe?

Authors:  Christian Cadet; Emmanuel Maheu
Journal:  Ther Adv Musculoskelet Dis       Date:  2021-06-18       Impact factor: 5.346

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.